Payment overview · 2025
General Payments
$124.88
4 reported records · 2 companies
Healthcare provider profile · identity verified
Helen Rostamloo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GLENDALE, CA · NPI 1285759514
Verified facts
What the public records show
CMS Open Payments records show Helen Rostamloo, MD received $124.88 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 72.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.96 | 72.8% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $33.92 | 27.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.88 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $90.96 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $90.96 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $33.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 67 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
175 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 539 | 119 |
| Losartan Potassium | Losartan Potassium | 452 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 72 |
| Alendronate Sodium | Alendronate Sodium | 353 | 88 |
| Gabapentin | Gabapentin | 345 | 79 |
| Furosemide | Furosemide | 292 | 80 |
| Omeprazole | Omeprazole | 274 | 70 |
| Metformin Hcl | Metformin Hcl | 273 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 67 |
| Meloxicam | Meloxicam | 236 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 46 |
| Montelukast Sodium | Montelukast Sodium | 195 | 49 |
| Trazodone Hcl | Trazodone Hcl | 195 | 44 |
| Lisinopril | Lisinopril | 186 | 43 |
| Linzess | Linaclotide | 175 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 51 |
| Azithromycin | Azithromycin | 153 | 108 |
| Diclofenac Sodium | Diclofenac Sodium | 149 | 47 |
| Eliquis | Apixaban | 136 | 46 |
| Donepezil Hcl | Donepezil Hcl | 131 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 33 |
| Meclizine Hcl | Meclizine Hcl | 126 | 41 |
| Tramadol Hcl | Tramadol Hcl | 126 | 23 |
| Clonidine Hcl | Clonidine Hcl | 125 | 33 |
| Alprazolam | Alprazolam | 124 | 27 |
| Potassium Chloride | Potassium Chloride | 122 | 30 |
| Carvedilol | Carvedilol | 117 | 33 |
| Ibuprofen | Ibuprofen | 115 | 30 |
| Sertraline Hcl | Sertraline Hcl | 106 | 21 |
| Famotidine | Famotidine | 103 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 36 |
| Ezetimibe | Ezetimibe | 94 | 19 |
| Finasteride | Finasteride | 94 | 31 |
| Bupropion Xl | Bupropion Hcl | 93 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 24 |
| Atenolol | Atenolol | 92 | 20 |
| Prednisone | Prednisone | 85 | 69 |
| Lorazepam | Lorazepam | 81 | 24 |
| Vascepa | Icosapent Ethyl | 78 | suppressed |
| Clonidine | Clonidine | 77 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Simvastatin | Simvastatin | 71 | 17 |
| Creon | Lipase/Protease/Amylase | 67 | 12 |
| Glipizide | Glipizide | 67 | 15 |
| Tradjenta | Linagliptin | 67 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 19 |
| Januvia | Sitagliptin Phosphate | 66 | 16 |
| Memantine Hcl | Memantine Hcl | 60 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 17 |
| Naproxen | Naproxen | 58 | 27 |
| Hydrocortisone | Hydrocortisone | 56 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 11 |
| Propranolol Hcl | Propranolol Hcl | 56 | 12 |
| Baclofen | Baclofen | 55 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 55 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | suppressed |
| Jardiance | Empagliflozin | 53 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Glimepiride | Glimepiride | 49 | suppressed |
| Ranolazine Er | Ranolazine | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 14 |
| Allopurinol | Allopurinol | 46 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 12 |
| Valsartan | Valsartan | 39 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Procto-Med Hc | Hydrocortisone | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 13 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 12 |
| Fluocinonide | Fluocinonide | 21 | 13 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Prolia | Denosumab | 21 | 14 |
| Sucralfate | Sucralfate | 21 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | 11 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.88 · 4 records | ABBVIE INC. | CREON, LINZESS, Tymlos | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error